| Year |
Citation |
Score |
| 2024 |
Miranda AX, Kemp J, Davidson B, Bellomo SE, Agan V, Manoni A, Marchiò C, Croessmann S, Park BH, Hodges E. Genomic dissection and mutation-specific target discovery for breast cancer hotspot mutations. Biorxiv : the Preprint Server For Biology. PMID 38260414 DOI: 10.1101/2024.01.03.574067 |
0.414 |
|
| 2023 |
Foy R, Crozier L, Pareri AU, Valverde JM, Park BH, Ly T, Saurin AT. Oncogenic signals prime cancer cells for toxic cell overgrowth during a G1 cell cycle arrest. Molecular Cell. 83: 4047-4061.e6. PMID 37977117 DOI: 10.1016/j.molcel.2023.10.020 |
0.317 |
|
| 2022 |
Garcia-Recio S, Hinoue T, Wheeler GL, Kelly BJ, Garrido-Castro AC, Pascual T, De Cubas AA, Xia Y, Felsheim BM, McClure MB, Rajkovic A, Karaesmen E, Smith MA, Fan C, Ericsson PIG, ... ... Park BH, et al. Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. Nature Cancer. PMID 36585450 DOI: 10.1038/s43018-022-00491-x |
0.422 |
|
| 2022 |
Wong HY, Sheng Q, Hesterberg AB, Croessmann S, Rios BL, Giri K, Jackson J, Miranda AX, Watkins E, Schaffer KR, Donahue M, Winkler E, Penson DF, Smith JA, Herrell SD, ... ... Park BH, et al. Single cell analysis of cribriform prostate cancer reveals cell intrinsic and tumor microenvironmental pathways of aggressive disease. Nature Communications. 13: 6036. PMID 36229464 DOI: 10.1038/s41467-022-33780-1 |
0.326 |
|
| 2022 |
Altwegg KA, Viswanadhapalli S, Mann M, Chakravarty D, Krishnan SR, Liu Z, Liu J, Pratap UP, Ebrahimi B, Sanchez JR, Li X, Ma S, Park BH, Santhamma B, Chen Y, et al. A first-in-class inhibitor of ER coregulator PELP1 targets ER+ breast cancer. Cancer Research. PMID 35950923 DOI: 10.1158/0008-5472.CAN-22-0698 |
0.415 |
|
| 2022 |
Udden SN, Wang Q, Kumar S, Malladi VS, Wu SY, Wei S, Posner BA, Geboers S, Williams NS, Liu YL, Sharma JK, Mani RS, Malladi S, Parra K, Hofstad M, ... ... Park BH, et al. Targeting ESR1 mutation-Induced transcriptional addiction in breast cancer with BET inhibition. Jci Insight. PMID 35881485 DOI: 10.1172/jci.insight.151851 |
0.509 |
|
| 2022 |
Henry NL, Somerfield MR, Dayao Z, Elias A, Kalinsky K, McShane LM, Moy B, Park BH, Shanahan KM, Sharma P, Shatsky R, Stringer-Reasor E, Telli M, Turner NC, DeMichele A. Biomarkers for Systemic Therapy in Metastatic Breast Cancer: ASCO Guideline Update. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2201063. PMID 35759724 DOI: 10.1200/JCO.22.01063 |
0.349 |
|
| 2022 |
Liu MC, MacKay M, Kase M, Piwowarczyk A, Lo C, Schaeffer J, Finkle JD, Mason CE, Beaubier N, Blackwell KL, Park BH. Longitudinal Shifts of Solid Tumor and Liquid Biopsy Sequencing Concordance in Metastatic Breast Cancer. Jco Precision Oncology. 6: e2100321. PMID 35721584 DOI: 10.1200/PO.21.00321 |
0.346 |
|
| 2022 |
Dang DK, Park BH. Circulating tumor DNA: current challenges for clinical utility. The Journal of Clinical Investigation. 132. PMID 35703177 DOI: 10.1172/JCI154941 |
0.31 |
|
| 2022 |
Cravero K, Pantone MV, Shin DH, Bergman R, Cochran R, Chu D, Zabransky DJ, Karthikeyan S, Waters IG, Hunter N, Rosen DM, Kyker-Snowman K, Dalton WB, Button B, Shinn D, ... ... Park BH, et al. PEST domain variants are responsive to standard of care treatments despite distinct transformative properties in a breast cancer model. Oncotarget. 13: 373-386. PMID 35186194 DOI: 10.18632/oncotarget.28200 |
0.39 |
|
| 2022 |
Li Z, Wu Y, Yates ME, Tasdemir N, Bahreini A, Chen J, Levine KM, Priedigkeit NM, Nasrazadani A, Ali S, Buluwela L, Arnesen S, Gertz J, Richer JK, Troness B, ... ... Park BH, et al. Hotspot ESR1 mutations are multimodal and contextual modulators of breast cancer metastasis. Cancer Research. PMID 35078818 DOI: 10.1158/0008-5472.CAN-21-2576 |
0.548 |
|
| 2022 |
Sun S, Brazhnik K, Lee M, Maslov AY, Zhang Y, Huang Z, Klugman S, Park BH, Vijg J, Montagna C. Single-cell analysis of somatic mutation burden in mammary epithelial cells of pathogenic BRCA1/2 mutation carriers. The Journal of Clinical Investigation. PMID 35025760 DOI: 10.1172/JCI148113 |
0.52 |
|
| 2021 |
Walsh EM, Mangini N, Fetting J, Armstrong D, Chan IS, Connolly RM, Fiallos K, Lehman J, Nunes R, Petry D, Reynolds J, Shah M, Smith KL, Visvanathan K, Lauring J, ... Park BH, et al. Olaparib Use in Patients With Metastatic Breast Cancer Harboring Somatic BRCA1/2 Mutations or Mutations in Non-BRCA1/2, DNA Damage Repair Genes. Clinical Breast Cancer. PMID 35074264 DOI: 10.1016/j.clbc.2021.12.007 |
0.484 |
|
| 2021 |
De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Guarducci C, Malorni L, ... ... Park BH, et al. Correction: Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 27: 4939. PMID 34470810 DOI: 10.1158/1078-0432.CCR-21-2431 |
0.331 |
|
| 2021 |
Boudreau MW, Duraki D, Wang L, Mao C, Kim JE, Henn MA, Tang B, Fanning SW, Kiefer J, Tarasow TM, Bruckheimer EM, Moreno R, Mousses S, Greene GL, Roy EJ, ... Park BH, et al. A small-molecule activator of the unfolded protein response eradicates human breast tumors in mice. Science Translational Medicine. 13. PMID 34290053 DOI: 10.1126/scitranslmed.abf1383 |
0.43 |
|
| 2021 |
Ho WJ, Croessmann S, Lin J, Phyo ZH, Charmsaz S, Danilova L, Mohan AA, Gross NE, Chen F, Dong J, Aggarwal D, Bai Y, Wang J, He J, Leatherman JM, ... ... Park BH, et al. Systemic inhibition of PTPN22 augments anticancer immunity. The Journal of Clinical Investigation. PMID 34283806 DOI: 10.1172/JCI146950 |
0.316 |
|
| 2021 |
Zonneville J, Wang M, Alruwaili MM, Smith B, Melnick M, Eng KH, Melendy T, Park BH, Iyer R, Fountzilas C, Bakin AV. Selective therapeutic strategy for p53-deficient cancer by targeting dysregulation in DNA repair. Communications Biology. 4: 862. PMID 34253820 DOI: 10.1038/s42003-021-02370-0 |
0.368 |
|
| 2021 |
Croessmann S, Park BH. Circulating tumor DNA in early-stage breast cancer: new directions and potential clinical applications. Clinical Advances in Hematology & Oncology : H&O. 19: 155-161. PMID 33739964 |
0.316 |
|
| 2021 |
De Angelis C, Fu X, Cataldo ML, Nardone A, Pereira R, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Wang T, Hilsenbeck SG, Benelli M, Migliaccio I, Malorni L, Litchfield LM, ... ... Park BH, et al. Activation of the interferon signaling pathway is associated with resistance to CDK4/6 inhibitors and immune checkpoint activation in ER-positive breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 33536276 DOI: 10.1158/1078-0432.CCR-19-4191 |
0.372 |
|
| 2021 |
Karthikeyan S, Waters IG, Dennison L, Chu D, Donaldson J, Shin DH, Rosen DM, Gonzalez-Ericsson PI, Sanchez V, Sanders ME, Pantone MV, Bergman RE, Davidson BA, Reed SC, Zabransky DJ, ... ... Park B, et al. Hierarchical tumor heterogeneity mediated by cell contact between distinct genetic subclones. The Journal of Clinical Investigation. PMID 33529175 DOI: 10.1172/JCI143557 |
0.476 |
|
| 2020 |
Cotul EK, Zuo Q, Santaliz-Casiano A, Imir OB, Mogol AN, Tunc E, Duong K, Lee JK, Ramesh R, Odukoya E, Kesavadas MP, Ziogaite M, Smith BP, Mao C, Shapiro DJ, ... Park BH, et al. Combined Targeting of Estrogen Receptor Alpha and Exportin 1 in Metastatic Breast Cancers. Cancers. 12. PMID 32847042 DOI: 10.3390/Cancers12092397 |
0.493 |
|
| 2020 |
Laws MJ, Ziegler Y, Shahoei SH, Dey P, Kim SH, Yasuda M, Park BH, Nettles KW, Katzenellenbogen JA, Nelson ER, Katzenellenbogen BS. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors. Breast Cancer Research and Treatment. PMID 32277377 DOI: 10.1007/S10549-020-05629-Y |
0.572 |
|
| 2020 |
Hunter N, Croessmann S, Cravero K, Shinn D, Hurley PJ, Park BH. Undetectable Tumor Cell-Free DNA in a Patient With Metastatic Breast Cancer With Complete Response and Long-Term Remission. Journal of the National Comprehensive Cancer Network : Jnccn. 18: 375-379. PMID 32259780 DOI: 10.6004/Jnccn.2019.7381 |
0.489 |
|
| 2020 |
Croessmann S, Park BH. Variant Interpretation in Patients With Metastatic Breast Cancer-Reply. Jama Oncology. PMID 31999303 DOI: 10.1001/Jamaoncol.2019.6409 |
0.491 |
|
| 2020 |
Smyth LM, Zhou Q, Nguyen B, Yu C, Lepisto EM, Arnedos M, Hassett MJ, Lenoue-Newton ML, Blauvelt N, Dogan S, Micheel CM, Wathoo C, Horlings H, Hudecek J, Gross BE, ... ... Park BH, et al. Characteristics and outcome of AKT1 E17K-mutant breast cancer defined through AACR GENIE, a clinicogenomic registry. Cancer Discovery. PMID 31924700 DOI: 10.1158/2159-8290.Cd-19-1209 |
0.5 |
|
| 2020 |
Duraki D, Boudreau MW, Wang L, Mao C, Tang B, Ma L, Roy EJ, Fan TM, Park BH, Nelson ER, Hergenrother PJ, Shapiro DJ. OR05-05 Lethal ERα-Dependent Hyperactivation of the Unfolded Protein Response Induces Complete Regression Without Recurrence of Primary and Metastatic Breast Cancer Journal of the Endocrine Society. 4. DOI: 10.1210/Jendso/Bvaa046.653 |
0.548 |
|
| 2020 |
Vidula N, Nanda R, Miller K, Pohlmann PR, Abramson VG, Emens LA, Park BH, Liu MC, Goga A, Rugo HS. Immunotherapy and chemotherapy combination for chest wall disease: TBCRC 044 trial. Journal of Clinical Oncology. 38: TPS1114-TPS1114. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps1114 |
0.42 |
|
| 2020 |
Lander EM, Lehmann BD, Shah PD, Dees EC, Ballinger TJ, Pohlmann PR, Santa-Maria CA, Shyr Y, Mayer IA, Park BH, Pietenpol JA, Abramson VG. A phase II trial of atezolizumab (anti-PD-L1) with carboplatin in patients with metastatic triple-negative breast cancer (mTNBC). Journal of Clinical Oncology. 38: TPS1112-TPS1112. DOI: 10.1200/Jco.2020.38.15_Suppl.Tps1112 |
0.378 |
|
| 2020 |
Lavery JA, Panageas K, LeNoue-Newton M, Sweeney S, Sheffler-Collins S, Rudolph JE, Rizvi H, Schultz N, Lepisto EM, Kehl KL, Warner JL, Dang K, Phillip J, Park BH, Riely GJ, et al. Progression-free survival estimates in non-small cell lung cancer when RECIST is unavailable: Project GENIE’s integration of genomic, therapeutic and phenomic data. Journal of Clinical Oncology. 38: 9622-9622. DOI: 10.1200/Jco.2020.38.15_Suppl.9622 |
0.379 |
|
| 2020 |
Shah M, Ensminger J, Wang C, Ali S, Chung J, Lauring J, Park BH, Stearns V. Abstract P6-10-07: Activating HER2 missense mutations in HER2-negative metastatic breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P6-10-07 |
0.555 |
|
| 2020 |
Hunter N, Parsons H, Sherry A, Shinn D, Shin DH, Cole A, Cragnotti G, Groginski T, Leathers M, Richardson AL, Argani P, Wolff A, Cope L, Edelstein D, Holtrup F, ... ... Park BH, et al. Abstract P6-10-05: TBCRC 040: Pathologic response evaluation and detection in circulating tumor DNA (PREDICT DNA): Initial results piloting a tissue-biopsy independent method of identifying and monitoring tumor-specific mutations in early stage breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-P6-10-05 |
0.458 |
|
| 2020 |
Boudreau MW, Hergenrother PJ, Duraki D, Wang L, Mao C, Park BH, Fan TM, Nelson ER, Shapiro DJ, Moreno R, Bruckheimer E, Kiefer J, Tarasow TM. Abstract P5-05-16: Quantitative regression of estrogen receptor alpha positive breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-05-16 |
0.559 |
|
| 2020 |
Weipert CM, Rich TA, Nagy RJ, Croessmann S, Park BH, O'Shaughnessy J, Nezami M, Cristofanilli M, Bardia A, Lanman RB. Abstract P5-01-06: Cell-free DNA (cfDNA) analysis of ESR1-mutant advanced breast cancer (aBC): Impact of subsequent therapy on mutation persistence Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-P5-01-06 |
0.425 |
|
| 2020 |
Murthy RK, O'Brien BJ, Hess KR, Navin N, Johnson J, Gule-Monroe M, Leone JP, Specht J, Melisko M, Morikawa A, Storniolo AM, Brufsky A, Pohlmann PR, Park DM, Park BH, et al. Abstract OT2-01-02: TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer TBCRC049: A phase II non-randomized study to assess the safety and efficacy of the combination of tucatinib and trastuzumab and capecitabine for treatment of leptomeningeal metastases in HER2 positive breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs19-Ot2-01-02 |
0.397 |
|
| 2020 |
King TA, Liu MC, McClure MB, Hinoue T, Kelly BJ, Creighton CJ, Bowen J, Leraas K, Burns RT, Coppens S, Rezk S, Garrett AL, Balko JM, Parker JS, Park BH, et al. Abstract GS3-08: Multiplatform analysis of matched primary and metastatic breast tumors from the AURORA US Network Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs3-08 |
0.514 |
|
| 2020 |
Angelis CD, Fu X, Cataldo ML, Nardone A, Jansen VM, Veeraraghavan J, Nanda S, Qin L, Sethunath V, Pereira R, Benelli M, Migliaccio I, Malorni L, Donaldson J, Selenica P, ... ... Park BH, et al. Abstract GS2-01: High levels of interferon-response gene signatures are associated with de novo and acquired resistance to CDK4/6 inhibitors in ER+ breast cancer Cancer Research. 80. DOI: 10.1158/1538-7445.Sabcs19-Gs2-01 |
0.515 |
|
| 2020 |
Karthikeyan S, Waters I, Dennison L, Chu D, Donaldson J, Shinn DH, Croessmann S, Park BH. Abstract 1498: Fibronectin mediates mutation specific interactions between subclonal populations of mutantPIK3CAandHER2cells in breast cancer Tumor Biology. DOI: 10.1158/1538-7445.Am2020-1498 |
0.524 |
|
| 2019 |
Kyker-Snowman K, Hughes RM, Yankaskas CL, Cravero K, Karthikeyan S, Button B, Waters I, Rosen DM, Dennison L, Hunter N, Donaldson J, Christenson ES, Konstantopoulos K, Hurley PJ, Croessmann S, ... Park BH, et al. TrkA overexpression in non-tumorigenic human breast cell lines confers oncogenic and metastatic properties. Breast Cancer Research and Treatment. PMID 31823098 DOI: 10.1007/S10549-019-05506-3 |
0.562 |
|
| 2019 |
Wang F, Reid S, Zheng W, Pal T, Meszoely I, Mayer IA, Bailey CE, Park BH, Shu XO. Sex Disparity Observed for Oncotype DX Breast Recurrence Score in Predicting Mortality Among Patients with Early Stage ER-Positive Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 31748278 DOI: 10.1158/1078-0432.Ccr-19-2424 |
0.444 |
|
| 2019 |
Stuttgen K, Croessmann S, Fetting J, Stearns V, Nunes R, Connolly RM, Park BH. Pathogenic Germline Variants in Patients With Metastatic Breast Cancer. Jama Oncology. PMID 31465090 DOI: 10.1001/Jamaoncol.2019.3116 |
0.497 |
|
| 2019 |
Dalton WB, Helmenstine E, Walsh N, Gondek LP, Kelkar DS, Read A, Natrajan R, Christenson ES, Roman B, Das S, Zhao L, Leone RD, Shinn D, Groginski T, Madugundu AK, ... ... Park B, et al. Hotspot SF3B1 mutations induce metabolic reprogramming and vulnerability to serine deprivation. The Journal of Clinical Investigation. 130. PMID 31393856 DOI: 10.1172/Jci125022 |
0.471 |
|
| 2019 |
Karthikeyan S, Park BH. Circulating Tumor DNA as a Marker for Disease Relapse in Early-Stage Breast Cancer-Bad Blood. Jama Oncology. PMID 31369044 DOI: 10.1001/Jamaoncol.2019.2047 |
0.433 |
|
| 2019 |
Hughes RM, Simons BW, Khan H, Miller R, Kugler V, Torquato S, Theodros D, Haffner MC, Lotan TL, Huang J, Davicioni E, An SS, Riddle RC, Thorek DL, Garraway IP, ... ... Park BH, et al. Asporin Restricts Mesenchymal Stromal Cell Differentiation, Alters the Tumor Microenvironment, and Drives Metastatic Progression. Cancer Research. PMID 31123087 DOI: 10.1158/0008-5472.Can-18-2931 |
0.399 |
|
| 2019 |
Zhang X, Wang Y, Chiang HC, Hsieh YP, Lu C, Park BH, Jatoi I, Jin VX, Hu Y, Li R. BRCA1 mutations attenuate super-enhancer function and chromatin looping in haploinsufficient human breast epithelial cells. Breast Cancer Research : Bcr. 21: 51. PMID 30995943 DOI: 10.1186/S13058-019-1132-1 |
0.576 |
|
| 2019 |
Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey LA, Liu MC, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Krop IE, ... ... Park BH, et al. TBCRC026: Phase II Trial Correlating Standardized Uptake Value With Pathologic Complete Response to Pertuzumab and Trastuzumab in Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. JCO2018787986. PMID 30721110 DOI: 10.1200/Jco.2018.78.7986 |
0.443 |
|
| 2019 |
Lauring J, Park BH. TORn in Two Over Breast Cancer Drug Resistance. Oncology (Williston Park, N.Y.). 27. PMID 25188239 |
0.334 |
|
| 2019 |
Katzenellenbogen J, Min J, Kim S, Laws M, Zhao Y, Ziegler Y, Nelson E, Shahoei S, Chu D, Park B, Katzenellenbogen B. Abstract P5-04-06: Withdrawn Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P5-04-06 |
0.434 |
|
| 2019 |
Shah M, Hunter N, Ensminger J, Shinn D, Cole A, Quinn H, Edelstein D, Wang C, Smith K, Richardson A, Cimino-Mathews A, Wolff A, Cravero K, Park B, Stearns V. Abstract P4-01-16: Detection of plasma tumor DNA (ptDNA) in patients with hormone receptor-positive HER2-negative (HR+HER2-) early breast cancer (EBC) in clinical remission Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-P4-01-16 |
0.457 |
|
| 2019 |
Li Z, Bahreini A, Levine K, Wang P, Tasdemir N, Montanez M, Sundd P, Wallace C, Watkins S, Chu D, Park B, Hou W, Zhu L, Tseng G, Carroll J, et al. Abstract P2-01-09: ESR1 mutations drive breast cancer metastasis by context-dependent alterations in adhesive and migratory properties Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-P2-01-09 |
0.573 |
|
| 2019 |
Vidula N, Goga A, Hwang J, Liu M, Park B, Nanda R, Pohlmann P, Storniolo A, Brufsky A, Abramson V, Rugo H. Abstract OT3-04-04: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies Cancer Research. 79. DOI: 10.1158/1538-7445.Sabcs18-Ot3-04-04 |
0.453 |
|
| 2019 |
Waters I, Karthikeyan S, Dennison L, Chu D, Park BH. Abstract 5149: Subclonal sociability: Interactions ofHER2andPIK3CAmutant cells in breast cancer Cancer Research. DOI: 10.1158/1538-7445.Sabcs18-5149 |
0.508 |
|
| 2018 |
Button B, Croessmann S, Chu D, Rosen DM, Zabransky DJ, Dalton WB, Cravero K, Kyker-Snowman K, Waters I, Karthikeyan S, Christenson ES, Donaldson J, Hunter T, Dennison L, Ramin C, ... ... Park BH, et al. The estrogen receptor-alpha S118P variant does not affect breast cancer incidence or response to endocrine therapies. Breast Cancer Research and Treatment. PMID 30560461 DOI: 10.1007/S10549-018-05087-7 |
0.488 |
|
| 2018 |
Yu L, Wang L, Mao C, Duraki D, Kim JE, Huang R, Helferich WG, Nelson ER, Park BH, Shapiro DJ. Estrogen-Independent Myc Overexpression Confers Endocrine Therapy Resistance on Breast Cancer Cells Expressing ERαY537S and ERαD538G Mutations. Cancer Letters. PMID 30419347 DOI: 10.1016/J.Canlet.2018.10.041 |
0.617 |
|
| 2018 |
Gucalp A, Traina TA, Eisner JR, Parker JS, Selitsky SR, Park BH, Elias AD, Baskin-Bey ES, Cardoso F. Male breast cancer: a disease distinct from female breast cancer. Breast Cancer Research and Treatment. PMID 30267249 DOI: 10.1007/S10549-018-4921-9 |
0.449 |
|
| 2018 |
Stearns V, Park BH. PIK3CA Mutations in Hormone Receptor-Positive Breast Cancers: PIKing Biomarkers to Inform Adjuvant Endocrine Therapy Decisions. Jama Oncology. PMID 29902310 DOI: 10.1001/Jamaoncol.2018.1766 |
0.488 |
|
| 2018 |
Medford AJ, Gillani RN, Park BH. Detection of Cancer DNA in Early Stage and Metastatic Breast Cancer Patients. Methods in Molecular Biology (Clifton, N.J.). 1768: 209-227. PMID 29717446 DOI: 10.1007/978-1-4939-7778-9_13 |
0.523 |
|
| 2018 |
Kyker-Snowman K, Erlanger Avigdor B, Nasim M, Cimino-Mathews A, Wheelan SJ, Argani P, Park BH. A primary breast cancer with distinct foci of estrogen receptor-alpha positive and negative cells derived from the same clonal origin as revealed by whole exome sequencing. Breast Cancer Research and Treatment. PMID 29541976 DOI: 10.1007/S10549-018-4742-X |
0.519 |
|
| 2018 |
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, Morley S, Rosenzweig M, Gay LM, Goldberg ME, Suh J, Ali S, Ross J, Leyland-Jones B, Young B, ... ... Park B, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy resistant breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 29360925 DOI: 10.1093/Annonc/Mdy025 |
0.468 |
|
| 2018 |
Alhuqail AJ, Alzahrani A, Almubarak H, Al-Qadheeb S, Alghofaili L, Almoghrabi N, Alhussaini H, Park BH, Colak D, Karakas B. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients. Breast Cancer Research and Treatment. PMID 29297111 DOI: 10.1007/S10549-017-4635-4 |
0.573 |
|
| 2018 |
Vidula N, Goga A, Hwang J, Liu MC, Park BH, Nanda R, Pohlmann PR, Storniolo AM, Brufsky A, Abramson VG, Rugo HS. A randomized phase II study of pembrolizumab, an anti-PD (programmed cell death) 1 antibody, in combination with carboplatin compared to carboplatin alone in breast cancer patients with chest wall disease, with immunologic and genomic correlative studies. Journal of Clinical Oncology. 36: TPS1113-TPS1113. DOI: 10.1200/Jco.2018.36.15_Suppl.Tps1113 |
0.458 |
|
| 2018 |
Li Z, Bahreini A, Wang P, Levine KM, Tasdemir N, Chu D, Park BH, Lee AV, Oesterreich S. Abstract PD8-08: ESR1 mutations confer novel metastatic functions in genome-edited breast cancer cell models Cancer Research. 78: 1001-1001. DOI: 10.1158/1538-7445.Sabcs17-Pd8-08 |
0.608 |
|
| 2018 |
Vidula N, Goga A, Krummel M, Hwang J, Liu M, Park B, Nanda R, Pohlmann P, Storniolo A, Poznak CV, Brufsky A, Abramson V, Wolff A, Rugo H. Abstract OT1-02-03: TBCRC 044: A randomized phase II study of pembrolizumab in combination with carboplatin versus carboplatin alone in breast cancer patients with chest wall disease Cancer Research. 78. DOI: 10.1158/1538-7445.Sabcs17-Ot1-02-03 |
0.401 |
|
| 2018 |
Laws MJ, Kim SH, Min J, Zhao Y, Ziegler Y, Chu D, Park BH, Katzenellenbogen JA, Katzenellenbogen BS. Abstract 946: Suppression of breast cancer metastasis and extension of host animal survival by a new adamantyl antiestrogen, K-07, in a preclinical breast cancer metastasis model driven by constitutively active mutant estrogen receptors Cancer Research. 78: 946-946. DOI: 10.1158/1538-7445.Am2018-946 |
0.531 |
|
| 2017 |
Avigdor BE, Cimino-Mathews A, DeMarzo AM, Hicks JL, Shin J, Sukumar S, Fetting J, Argani P, Park BH, Wheelan SJ. Mutational profiles of breast cancer metastases from a rapid autopsy series reveal multiple evolutionary trajectories. Jci Insight. 2. PMID 29263308 DOI: 10.1172/Jci.Insight.96896 |
0.507 |
|
| 2017 |
Paoletti C, Cani AK, Larios JM, Hovelson DH, Aung K, Darga EP, Cannell EM, Baratta PJ, Liu CJ, Chu D, Yazdani M, Blevins AR, Sero V, Tokudome N, Thomas DG, ... ... Park BH, et al. Comprehensive mutation and copy number profiling in archived circulating breast cancer tumor cells documents heterogeneous resistance mechanisms. Cancer Research. PMID 29233927 DOI: 10.1158/0008-5472.Can-17-2686 |
0.511 |
|
| 2017 |
Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC. ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Oncotarget. 8: 83432-83445. PMID 29137354 DOI: 10.18632/Oncotarget.12735 |
0.547 |
|
| 2017 |
Li Z, Levine KM, Bahreini A, Wang P, Chu D, Park BH, Oesterreich S, Lee AV. Upregulation of IRS1 enhances IGF1 response in Y537S and D538G ESR1 mutant breast cancer cells. Endocrinology. PMID 29029116 DOI: 10.1210/En.2017-00693 |
0.532 |
|
| 2017 |
Chung JH, Pavlick D, Hartmaier R, Schrock AB, Young L, Forcier B, Ye P, Levin MK, Burris H, Gay LM, Hoffman AD, Stephens PJ, Frampton GM, Lipson DM, Nguyen DM, ... ... Park BH, et al. Hybrid capture-based genomic profiling of circulating tumor DNA from patients with estrogen receptor-positive metastatic breast cancer. Annals of Oncology : Official Journal of the European Society For Medical Oncology. PMID 28945887 DOI: 10.1093/Annonc/Mdx490 |
0.466 |
|
| 2017 |
Katzenellenbogen BS, Zhao Y, Laws MJ, Sanabria Guillen V, Ziegler Y, Min J, Sharma A, Kim SH, Chu D, Park BH, Oesterreich S, Mao C, Shapiro DJ, Nettles KW, Katzenellenbogen JA. Structurally novel antiestrogens elicit differential responses from constitutively active mutant estrogen receptors in breast cancer cells and tumors. Cancer Research. PMID 28904064 DOI: 10.1158/0008-5472.Can-17-1265 |
0.516 |
|
| 2017 |
Donaldson J, Park BH. Circulating Tumor DNA: Measurement and Clinical Utility. Annual Review of Medicine. PMID 28846488 DOI: 10.1146/Annurev-Med-041316-085721 |
0.429 |
|
| 2017 |
Bahreini A, Li Z, Wang P, Levine KM, Tasdemir N, Cao L, Weir HM, Puhalla SL, Davidson NE, Stern AM, Chu D, Park BH, Lee AV, Oesterreich S. Mutation site and context dependent effects of ESR1 mutation in genome-edited breast cancer cell models. Breast Cancer Research : Bcr. 19: 60. PMID 28535794 DOI: 10.1186/S13058-017-0851-4 |
0.605 |
|
| 2017 |
Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang NJ, Ng CKY, Chen E, Renwick A, Wang T, Nanda S, ... ... Park BH, et al. HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28487443 DOI: 10.1158/1078-0432.Ccr-16-2191 |
0.515 |
|
| 2017 |
Chu D, Park BH. Liquid biopsy: unlocking the potentials of cell-free DNA. Virchows Archiv : An International Journal of Pathology. PMID 28466157 DOI: 10.1007/S00428-017-2137-8 |
0.366 |
|
| 2017 |
Avigdor B, Beierl K, Gocke CD, Zabransky D, Cravero K, Kyker-Snowman K, Button B, Chu D, Croessmann S, Cochran RL, Connolly R, Park BH, Cimino-Mathews A, Wheelan SJ. Whole exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28424200 DOI: 10.1158/1078-0432.Ccr-17-0108 |
0.512 |
|
| 2017 |
Husain H, Melnikova VO, Kosco K, Woodward B, More S, Pingle SC, Weihe E, Park BH, Tewari M, Erlander MG, Cohen EEW, Lippman SM, Kurzrock R. Monitoring Daily Dynamics of Early Tumor Response to Targeted Therapy by Detecting Circulating Tumor DNA in Urine. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 28420725 DOI: 10.1158/1078-0432.Ccr-17-0454 |
0.397 |
|
| 2017 |
Croessmann S, Wong HY, Zabransky DJ, Chu D, Rosen DM, Cidado J, Cochran RL, Dalton WB, Erlanger B, Cravero K, Button B, Kyker-Snowman K, Hurley PJ, Lauring J, Park BH. PIK3CA mutations and TP53 alterations cooperate to increase cancerous phenotypes and tumor heterogeneity. Breast Cancer Research and Treatment. PMID 28190247 DOI: 10.1007/S10549-017-4147-2 |
0.758 |
|
| 2017 |
Goldstein A, Valda Toro P, Lee J, Silberstein JL, Nakazawa M, Waters I, Cravero K, Chu D, Cochran RL, Kim M, Shinn D, Torquato S, Hughes RM, Pallavajjala A, Carducci MA, ... ... Park BH, et al. Detection fidelity of AR mutations in plasma derived cell-free DNA. Oncotarget. PMID 28152506 DOI: 10.18632/Oncotarget.14926 |
0.425 |
|
| 2017 |
Canzoniero JV, Cravero K, Park BH. The Impact of Collisions on the Ability to Detect Rare Mutant Alleles Using Barcode-Type Next-Generation Sequencing Techniques Cancer Informatics. 16: 117693511771923. DOI: 10.1177/1176935117719236 |
0.323 |
|
| 2017 |
Park B. Abstract PL2: Cell free plasma tumor DNA in breast oncology Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pl2 |
0.42 |
|
| 2017 |
Croessmann S, Zabransky D, Cutler R, Lalani A, Park B, Arteaga C. Abstract PD2-05: Inhibition of mutant HER2 results in synthetic lethality when combined with ER antagonists in ER+/HER2 mutant human breast cancer cells Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-Pd2-05 |
0.597 |
|
| 2017 |
Benz C, Scott G, Chu D, Malato J, Hann B, Park B. Abstract P6-11-01: CDK2 inhibition prevents ERpS294 and restores the ability of tamoxifen to induce regression in breast tumors expressing mutantESR1 Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-11-01 |
0.43 |
|
| 2017 |
Avigdor BE, Beierl K, Gocke CD, Zabransky DJ, Cravero K, Kyker-Snowmana K, Button B, Chu D, Croessmann S, Cochran RL, Connolly RM, Park BH, Cimino-Mathews A, Wheelan SJ. Abstract LB-278: Whole exome sequencing of metaplastic breast carcinoma indicates monoclonality with associated ductal carcinoma component Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-278 |
0.496 |
|
| 2017 |
Schram A, Won HH, Andre F, Arnedos M, Bernstam FM, Bedard PL, Shaw KR, Horlings H, Micheel C, Park BH, Mann G, Lalani AS, Smyth L, Solit DB, Schrag D, et al. Abstract LB-103: Landscape of somatic ERBB2 Mutations: Findings from AACR GENIE and comparison to ongoing ERBB2 mutant basket study Cancer Research. 77. DOI: 10.1158/1538-7445.Am2017-Lb-103 |
0.543 |
|
| 2017 |
Li Z, Bahreini A, Wang P, Levine K, Tasdemir N, Chu D, Park BH, Lee A, Oesterreich S. Abstract 1001: ESR1 mutations confer novel metastatic functions in genome-edited breast cancer models Endocrinology. DOI: 10.1158/1538-7445.Am2017-1001 |
0.54 |
|
| 2016 |
Button B, Park BH. mutations: Pièce de résistance. Genes & Diseases. 3: 124-129. PMID 30258881 DOI: 10.1016/j.gendis.2016.03.005 |
0.356 |
|
| 2016 |
Kim HS, Umbricht CB, Illei PB, Cimino-Mathews A, Cho S, Chowdhury N, Figueroa-Magalhaes MC, Pesce C, Jeter SC, Mylander C, Rosman M, Tafra L, Turner BM, Hicks DG, Jensen TA, ... ... Park BH, et al. Optimizing the Use of Gene Expression Profiling in Early-Stage Breast Cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 34: 4390-4397. PMID 27998227 DOI: 10.1200/Jco.2016.67.7195 |
0.311 |
|
| 2016 |
Lee J, Axilbund J, Dalton WB, Laheru D, Watkins S, Chu D, Cravero K, Button B, Kyker-Snowman K, Waters I, Gocke CD, Lauring J, Park BH. A Polycythemia Vera JAK2 Mutation Masquerading as a Duodenal Cancer Mutation. Journal of the National Comprehensive Cancer Network : Jnccn. 14: 1495-1498. PMID 27956534 DOI: 10.6004/Jnccn.2016.0161 |
0.513 |
|
| 2016 |
Scott GK, Chu D, Kaur R, Malato J, Rothschild DE, Frazier K, Eppenberger-Castori S, Hann B, Park BH, Benz CC. ERpS294 is a biomarker of ligand or mutational ERα activation and a breast cancer target for CDK2 inhibition. Oncotarget. PMID 27765908 DOI: 10.18632/oncotarget.12735 |
0.457 |
|
| 2016 |
Parsons HA, Beaver JA, Cimino-Mathews A, Ali SM, Axilbund J, Chu D, Connolly R, Cochran R, Croessmann S, Clark T, Gocke CD, Jeter SC, Kennedy M, Lauring J, Lee J, ... ... Park BH, et al. Individualized Molecular Analyses Guide Efforts (IMAGE): A Prospective Study of Molecular Profiling of Tissue and Blood in Metastatic Triple Negative Breast Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27489289 DOI: 10.1158/1078-0432.Ccr-16-1543 |
0.488 |
|
| 2016 |
VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P. Reflex Estrogen Receptor (ER) and Progesterone Receptor (PR) Analysis of Ductal Carcinoma In Situ (DCIS) in Breast Needle Core Biopsy Specimens: An Unnecessary Exercise That Costs the United States $35 Million/y. The American Journal of Surgical Pathology. PMID 27299796 DOI: 10.1097/Pas.0000000000000674 |
0.3 |
|
| 2016 |
Canzoniero JV, Park BH. Use of cell free DNA in breast oncology. Biochimica Et Biophysica Acta. PMID 27012505 DOI: 10.1016/J.Bbcan.2016.03.006 |
0.541 |
|
| 2016 |
Parsons HA, Beaver JA, Park BH. Circulating Plasma Tumor DNA. Advances in Experimental Medicine and Biology. 882: 259-76. PMID 26987539 DOI: 10.1007/978-3-319-22909-6_11 |
0.399 |
|
| 2016 |
Cidado J, Wong HY, Rosen DM, Cimino-Mathews A, Garay JP, Fessler AG, Rasheed ZA, Hicks J, Cochran RL, Croessmann S, Zabransky DJ, Mohseni M, Beaver JA, Chu D, Cravero K, ... ... Park BH, et al. Ki-67 is required for maintenance of cancer stem cells but not cell proliferation. Oncotarget. PMID 26823390 DOI: 10.18632/Oncotarget.7057 |
0.83 |
|
| 2016 |
Argani P, Lee J, Netto GJ, Zheng G, Tseh-Lin M, Park BH. Frequent BRAF V600E Mutations in Metanephric Stromal Tumor. The American Journal of Surgical Pathology. PMID 26796506 DOI: 10.1097/Pas.0000000000000603 |
0.405 |
|
| 2016 |
St. Louis J, Bukowski A, Ruiz Mendoza RE, Herrero Vincent C, Hernandez Blanquisett A, Taghian AG, Stearns V, Connolly R, Park BH, Marquez C, Schmeler KM, Jhingran A, del Carmen MG, Randall TC, Dizon DS, et al. Global Cancer Institute (GCI) multi-disciplinary tumor boards (MTBs) as an educational tool to improve guideline-based cancer clinical practice in low- and middle-income countries (LMICs). Journal of Clinical Oncology. 34: e18007-e18007. DOI: 10.1200/Jco.2016.34.15_Suppl.E18007 |
0.339 |
|
| 2016 |
Parsons H, Beaver J, Cimino-Mathews A, Zorzi J, Slater S, Clark T, Lipson D, Ali S, Kennedy M, Otto G, Young L, Jeter S, VanDenBerg D, Rosner G, Park B, et al. Abstract PD6-08: IMAGE: Individualized molecular analyses guide efforts in breast cancer with comprehensive genomic profiling of tissue and plasma tumor DNA Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd6-08 |
0.438 |
|
| 2016 |
Benz C, Scott G, Chu D, Kaur R, Muthurajah M, Rothschild D, Frazier K, Park B. Abstract PD2-04: ERα phosphorylation at pS294: A biomarker of ligand or mutational (Y537S, D538G) activation, and a receptor target for CDK2 inhibition Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-Pd2-04 |
0.497 |
|
| 2016 |
Paoletti C, Aung K, Cannell E, Darga E, Chu D, Kidwell K, Thomas D, Tokudome N, Brown M, McNutt L, Gersch C, Schott A, Park B, Robinson, Chinnaiyan A, et al. Abstract P3-05-01: Molecular analysis of cancer tissue, circulating tumor cells (CTC) and cell-free plasma tumor DNA (ptDNA) suggests variable mechanisms of resistance to endocrine therapy (ET) in estrogen receptor (ER) positive metastatic breast cancer (MBC) Cancer Research. 76. DOI: 10.1158/1538-7445.Sabcs15-P3-05-01 |
0.501 |
|
| 2016 |
Button B, Park BH. ESR1 mutations: Pièce de résistance Genes and Diseases. 3: 124-129. DOI: 10.1016/J.Gendis.2016.03.005 |
0.462 |
|
| 2016 |
Kyker-Snowman K, Park BH. WITHDRAWN: Preanalytical and analytical considerations of circulating plasma tumor DNA for breast oncology Computational and Structural Biotechnology Journal. DOI: 10.1016/J.Csbj.2016.02.002 |
0.385 |
|
| 2016 |
Cravero K, Park BH. Circulating Tumor DNA—the Potential of Liquid Biopsies Current Breast Cancer Reports. 1-8. DOI: 10.1007/S12609-016-0199-2 |
0.411 |
|
| 2015 |
Wong HY, Wang GM, Croessmann S, Zabransky DJ, Chu D, Garay JP, Cidado J, Cochran RL, Beaver JA, Aggarwal A, Liu ML, Argani P, Meeker A, Hurley PJ, Lauring J, ... Park BH, et al. TMSB4Y is a candidate tumor suppressor on the Y chromosome and is deleted in male breast cancer. Oncotarget. PMID 26702755 DOI: 10.18632/Oncotarget.6743 |
0.84 |
|
| 2015 |
Zabransky DJ, Yankaskas CL, Cochran RL, Wong HY, Croessmann S, Chu D, Kavuri SM, Red Brewer M, Rosen DM, Dalton WB, Cimino-Mathews A, Cravero K, Button B, Kyker-Snowman K, Cidado J, ... ... Park BH, et al. HER2 missense mutations have distinct effects on oncogenic signaling and migration. Proceedings of the National Academy of Sciences of the United States of America. PMID 26508629 DOI: 10.1073/Pnas.1516853112 |
0.788 |
|
| 2015 |
Hurley PJ, Sundi D, Shinder B, Simons B, Hughes RM, Miller RM, Benzon B, Faraj SF, Netto GJ, Vergara IA, Erho N, Davicioni E, Karnes RJ, Yan G, Ewing CM, ... ... Park BH, et al. Germline Variants in Asporin Vary by Race, Modulate the Tumor Microenvironment and are Differentially Associated with Metastatic Prostate Cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26446945 DOI: 10.1158/1078-0432.Ccr-15-0256 |
0.348 |
|
| 2015 |
Croessmann S, Wong HY, Zabransky DJ, Chu D, Mendonca J, Sharma A, Mohseni M, Rosen DM, Scharpf RB, Cidado J, Cochran RL, Parsons HA, Dalton WB, Erlanger B, Button B, ... ... Park BH, et al. NDRG1 links p53 with proliferation-mediated centrosome homeostasis and genome stability. Proceedings of the National Academy of Sciences of the United States of America. 112: 11583-8. PMID 26324937 DOI: 10.1073/Pnas.1503683112 |
0.821 |
|
| 2015 |
Zahari MS, Wu X, Blair BG, Pinto SM, Nirujogi RS, Jelinek CA, Malhotra R, Kim MS, Park BH, Pandey A. Activating mutations in PIK3CA lead to widespread modulation of the tyrosine phosphoproteome. Journal of Proteome Research. PMID 26267517 DOI: 10.1021/Acs.Jproteome.5B00302 |
0.776 |
|
| 2015 |
Chu D, Paoletti C, Gersch C, VanDenBerg D, Zabransky D, Cochran R, Wong HY, Valda Toro P, Cidado J, Croessmann S, Erlanger B, Cravero K, Kyker-Snowman K, Button B, Parsons H, ... ... Park BH, et al. ESR1 mutations in circulating plasma tumor DNA from metastatic breast cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26261103 DOI: 10.1158/1078-0432.Ccr-15-0943 |
0.787 |
|
| 2015 |
Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes. Oncotarget. PMID 26246475 DOI: 10.18632/Oncotarget.4595 |
0.775 |
|
| 2015 |
Beaver JA, Park BH. Detecting Plasma Tumor DNA in Early-Stage Breast Cancer-Reply. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 21: 3570. PMID 26240293 DOI: 10.1158/1078-0432.Ccr-15-0994 |
0.4 |
|
| 2015 |
Stearns V, Park BH. Gene Mutation Profiling of Breast Cancers for Clinical Decision Making: Drivers and Passengers in the Cart Before the Horse. Jama Oncology. PMID 26182336 DOI: 10.1001/jamaoncol.2015.0761 |
0.406 |
|
| 2015 |
Jhaveri TZ, Woo J, Shang X, Park BH, Gabrielson E. AMP-activated kinase (AMPK) regulates activity of HER2 and EGFR in breast cancer. Oncotarget. 6: 14754-65. PMID 26143491 DOI: 10.18632/Oncotarget.4474 |
0.547 |
|
| 2015 |
Young CD, Zimmerman LJ, Hoshino D, Formisano L, Hanker AB, Gatza ML, Morrison MM, Moore PD, Whitwell CA, Dave B, Stricker T, Bhola NE, Silva GO, Patel P, Brantley-Sieders DM, ... ... Park BH, et al. Activating PIK3CA Mutations Induce an Epidermal Growth Factor Receptor (EGFR)/Extracellular Signal-regulated Kinase (ERK) Paracrine Signaling Axis in Basal-like Breast Cancer. Molecular & Cellular Proteomics : McP. 14: 1959-76. PMID 25953087 DOI: 10.1074/Mcp.M115.049783 |
0.567 |
|
| 2015 |
VandenBussche CJ, Cimino-Mathews A, Park BH, Emens LA, Tsangaris TN, Argani P. Reflex Estrogen Receptor/Progesterone Receptor/Human Epidermal Growth Factor Receptor 2 (ER/PR/Her2) Analysis of Breast Cancers in Needle Core Biopsy Specimens Dramatically Increases Health Care Costs. The American Journal of Surgical Pathology. 39: 939-47. PMID 25871620 DOI: 10.1097/Pas.0000000000000424 |
0.367 |
|
| 2015 |
Blair BG, Wu X, Zahari MS, Mohseni M, Cidado J, Wong HY, Beaver JA, Cochran RL, Zabransky DJ, Croessmann S, Chu D, Toro PV, Cravero K, Pandey A, Park BH. A phosphoproteomic screen demonstrates differential dependence on HER3 for MAP kinase pathway activation by distinct PIK3CA mutations. Proteomics. 15: 318-26. PMID 25367220 DOI: 10.1002/Pmic.201400342 |
0.825 |
|
| 2015 |
Nguyen HN, Yang JM, Rahdar M, Keniry M, Swaney KF, Parsons R, Park BH, Sesaki H, Devreotes PN, Iijima M. A new class of cancer-associated PTEN mutations defined by membrane translocation defects. Oncogene. 34: 3737-43. PMID 25263454 DOI: 10.1038/Onc.2014.293 |
0.484 |
|
| 2015 |
Cochran RL, Cidado J, Kim M, Zabransky DJ, Croessmann S, Chu D, Wong HY, Beaver JA, Cravero K, Erlanger B, Parsons H, Heaphy CM, Meeker AK, Lauring J, Park BH. Functional isogenic modeling of BRCA1 alleles reveals distinct carrier phenotypes Oncotarget. 6: 25240-25251. DOI: 10.18632/oncotarget.4595 |
0.649 |
|
| 2015 |
Park BH. Abstract ES8-2: Circulating plasma tumor DNA as biomarkers for breast cancer therapy Cancer Research. 75. DOI: 10.1158/1538-7445.Sabcs14-Es8-2 |
0.449 |
|
| 2014 |
Mohseni M, Cidado J, Croessmann S, Cravero K, Cimino-Mathews A, Wong HY, Scharpf R, Zabransky DJ, Abukhdeir AM, Garay JP, Wang GM, Beaver JA, Cochran RL, Blair BG, Rosen DM, ... ... Park BH, et al. MACROD2 overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers. Proceedings of the National Academy of Sciences of the United States of America. 111: 17606-11. PMID 25422431 DOI: 10.1073/Pnas.1408650111 |
0.821 |
|
| 2014 |
Wong HY, Park BH. Plasma tumor DNA: on your markers, get set, go! Annals of Translational Medicine. 2: 2. PMID 25332978 DOI: 10.3978/J.Issn.2305-5839.2013.06.07 |
0.477 |
|
| 2014 |
Wu X, Renuse S, Sahasrabuddhe NA, Zahari MS, Chaerkady R, Kim MS, Nirujogi RS, Mohseni M, Kumar P, Raju R, Zhong J, Yang J, Neiswinger J, Jeong JS, Newman R, ... ... Park BH, et al. Activation of diverse signalling pathways by oncogenic PIK3CA mutations. Nature Communications. 5: 4961. PMID 25247763 DOI: 10.1038/Ncomms5961 |
0.829 |
|
| 2014 |
Nguyen HN, Yang JM, Afkari Y, Park BH, Sesaki H, Devreotes PN, Iijima M. Engineering ePTEN, an enhanced PTEN with increased tumor suppressor activities. Proceedings of the National Academy of Sciences of the United States of America. 111: E2684-93. PMID 24979808 DOI: 10.1073/Pnas.1409433111 |
0.438 |
|
| 2014 |
Forde PM, Cochran RL, Boikos SA, Zabransky DJ, Beaver JA, Meyer CF, Thornton KA, Montgomery EA, Lidor AO, Donehower RC, Park BH. Familial GI Stromal Tumor With Loss of Heterozygosity and Amplification of Mutant KIT. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. PMID 24868028 DOI: 10.1200/Jco.2013.51.6633 |
0.306 |
|
| 2014 |
Cochran RL, Cravero K, Chu D, Erlanger B, Toro PV, Beaver JA, Zabransky DJ, Wong HY, Cidado J, Croessmann S, Parsons HA, Kim M, Wheelan SJ, Argani P, Park BH. Analysis of BRCA2 loss of heterozygosity in tumor tissue using droplet digital polymerase chain reaction. Human Pathology. 45: 1546-50. PMID 24824029 DOI: 10.1016/J.Humpath.2014.03.013 |
0.703 |
|
| 2014 |
Savage KI, Matchett KB, Barros EM, Cooper KM, Irwin GW, Gorski JJ, Orr KS, Vohhodina J, Kavanagh JN, Madden AF, Powell A, Manti L, McDade SS, Park BH, Prise KM, et al. BRCA1 deficiency exacerbates estrogen-induced DNA damage and genomic instability. Cancer Research. 74: 2773-84. PMID 24638981 DOI: 10.1158/0008-5472.Can-13-2611 |
0.525 |
|
| 2014 |
Zabransky DJ, Park BH. Estrogen receptor and receptor tyrosine kinase signaling: use of combinatorial hormone and epidermal growth factor receptor/human epidermal growth factor receptor 2-targeted therapies for breast cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 32: 1084-6. PMID 24590645 DOI: 10.1200/Jco.2013.53.5070 |
0.541 |
|
| 2014 |
Beaver JA, Jelovac D, Balukrishna S, Cochran RL, Croessmann S, Zabransky DJ, Wong HY, Valda Toro P, Cidado J, Blair BG, Chu D, Burns T, Higgins MJ, Stearns V, Jacobs L, ... ... Park BH, et al. Detection of cancer DNA in plasma of patients with early-stage breast cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 2643-50. PMID 24504125 DOI: 10.1158/1078-0432.Ccr-13-2933 |
0.817 |
|
| 2014 |
Jelovac D, Beaver JA, Balukrishna S, Wong HY, Toro PV, Cimino-Mathews A, Argani P, Stearns V, Jacobs L, VanDenBerg D, Kessler J, Jeter S, Park BH, Wolff AC. A PIK3CA mutation detected in plasma from a patient with synchronous primary breast and lung cancers. Human Pathology. 45: 880-3. PMID 24444464 DOI: 10.1016/J.Humpath.2013.10.016 |
0.524 |
|
| 2014 |
Blair BG, Bardelli A, Park BH. Somatic alterations as the basis for resistance to targeted therapies Journal of Pathology. 232: 244-254. PMID 24114654 DOI: 10.1002/Path.4278 |
0.751 |
|
| 2014 |
Ma CX, Gao F, Naughton M, Pluard TJ, Sorscher S, Creekmore AN, Guo Z, Dehdashti F, Park BH, Lockhart AC, Doyle LA, Ellis MJ, Erlanger B. A phase I study of the AKT inhibitor MK-2206 plus hormonal therapy in postmenopausal women with estrogen receptor positive (ER+) metastatic breast cancer (MBC). Journal of Clinical Oncology. 32: 553-553. DOI: 10.1200/Jco.2014.32.15_Suppl.553 |
0.388 |
|
| 2014 |
Young CD, Zimmerman LJ, Gatza ML, Morrison MM, Whitwell CA, Bhola NE, Hanker AB, Stricker T, Patel P, Brantley-Sieders DM, Perou CM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract 970: Mass spectrometry analysis of PIK3CA mutant mammary epithelial cells identifies EGFR as a paracrine effector of PI3K in basal-like breast cancer Cancer Research. 74: 970-970. DOI: 10.1158/1538-7445.Am2014-970 |
0.592 |
|
| 2014 |
Samuels ML, Taly V, Balaj L, Das S, Park BH. Abstract 5316: Quantitative cancer analysis using digital PCR: Absolute counting of DNA (solid tumors and liquid biopsies in glioma, breast, and colon cancer) and RNA (mRNA and miRNA using One-Step RT-dPCR) Cancer Research. 74: 5316-5316. DOI: 10.1158/1538-7445.Am2014-5316 |
0.41 |
|
| 2013 |
Karakas B, Colak D, Kaya N, Ghebeh H, Al-Qasem A, Hendrayani F, Toulimat M, Al-Tweigeri T, Park BH, Aboussekhra A. Prevalence of PIK3CA mutations and the SNP rs17849079 in Arab breast cancer patients. Cancer Biology & Therapy. 14: 888-96. PMID 23982433 DOI: 10.4161/Cbt.25945 |
0.558 |
|
| 2013 |
Ghosh S, Varela L, Sood A, Park BH, Lotan TL. mTOR signaling feedback modulates mammary epithelial differentiation and restrains invasion downstream of PTEN loss. Cancer Research. 73: 5218-31. PMID 23774212 DOI: 10.1158/0008-5472.Can-13-0429 |
0.389 |
|
| 2013 |
Lauring J, Park BH, Wolff AC. The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer Jnccn Journal of the National Comprehensive Cancer Network. 11: 670-678. PMID 23744866 DOI: 10.6004/Jnccn.2013.0086 |
0.543 |
|
| 2013 |
Colak D, Nofal A, Albakheet A, Nirmal M, Jeprel H, Eldali A, Al-Tweigeri T, Tulbah A, Ajarim D, Malik OA, Inan MS, Kaya N, Park BH, Bin Amer SM. Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. Plos One. 8: e63204. PMID 23704896 DOI: 10.1371/Journal.Pone.0063204 |
0.445 |
|
| 2013 |
Wang GM, Wong HY, Konishi H, Blair BG, Abukhdeir AM, Gustin JP, Rosen DM, Denmeade SR, Rasheed Z, Matsui W, Garay JP, Mohseni M, Higgins MJ, Cidado J, Jelovac D, ... ... Park BH, et al. Single copies of mutant KRAS and mutant PIK3CA cooperate in immortalized human epithelial cells to induce tumor formation. Cancer Research. 73: 3248-61. PMID 23580570 DOI: 10.1158/0008-5472.Can-12-1578 |
0.815 |
|
| 2013 |
Cidado J, Beaver JA, Park BH. Needles in a haystack: finding recurrent genomic changes in breast cancer. Breast Cancer Research : Bcr. 14: 304. PMID 23425423 DOI: 10.1186/Bcr3364 |
0.756 |
|
| 2013 |
Cimino-Mathews A, Subhawong AP, Illei PB, Sharma R, Halushka MK, Vang R, Fetting JH, Park BH, Argani P. GATA3 expression in breast carcinoma: utility in triple-negative, sarcomatoid, and metastatic carcinomas. Human Pathology. 44: 1341-9. PMID 23375642 DOI: 10.1016/J.Humpath.2012.11.003 |
0.415 |
|
| 2013 |
Jin L, Hanigan CL, Wu Y, Wang W, Park BH, Woster PM, Casero RA. Loss of LSD1 (lysine-specific demethylase 1) suppresses growth and alters gene expression of human colon cancer cells in a p53- and DNMT1 (DNA methyltransferase 1)-independent manner Biochemical Journal. 449: 459-468. PMID 23072722 DOI: 10.1042/Bj20121360 |
0.458 |
|
| 2013 |
Beaver JA, Balukrishna S, Jelovac D, Higgins MJ, Jeter S, Stearns V, Wolff AC, Kessler J, VanDenBerg D, Valda Toro P, Argani P, Park BH. Sensitivity for detecting PIK3CA mutations in early-stage breast cancer with droplet digital PCR. Journal of Clinical Oncology. 31: 11019-11019. DOI: 10.1200/Jco.2013.31.15_Suppl.11019 |
0.494 |
|
| 2013 |
Young CD, Zimmerman LJ, Whitwell CA, Hanker AB, Stricker T, Brantley-Sieders DM, Park BH, Liebler DC, Cook RS, Arteaga CL. Abstract B015: Knock-in of PIK3CA mutations in MCF10A mammary epithelial cells modifies their proteomic profile to resemble basal-like breast cancer and stimulate EGFR-dependent cell proliferation Molecular Cancer Research. 11. DOI: 10.1158/1557-3125.Advbc-B015 |
0.596 |
|
| 2012 |
Cimino-Mathews A, Subhawong AP, Elwood H, Warzecha HN, Sharma R, Park BH, Taube JM, Illei PB, Argani P. Neural crest transcription factor Sox10 is preferentially expressed in triple-negative and metaplastic breast carcinomas. Human Pathology. 44: 959-65. PMID 23260325 DOI: 10.1016/J.Humpath.2012.09.005 |
0.382 |
|
| 2012 |
Hurley PJ, Marchionni L, Simons BW, Ross AE, Peskoe SB, Miller RM, Erho N, Vergara IA, Ghadessi M, Huang Z, Gurel B, Park BH, Davicioni E, Jenkins RB, Platz EA, et al. Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome. Proceedings of the National Academy of Sciences of the United States of America. 109: 14977-82. PMID 22927397 DOI: 10.1073/Pnas.1203525109 |
0.333 |
|
| 2012 |
Cidado J, Park BH. Targeting the PI3K/Akt/mTOR pathway for breast cancer therapy Journal of Mammary Gland Biology and Neoplasia. 17: 205-216. PMID 22865098 DOI: 10.1007/S10911-012-9264-2 |
0.78 |
|
| 2012 |
Garay JP, Park BH. Androgen receptor as a targeted therapy for breast cancer. American Journal of Cancer Research. 2: 434-45. PMID 22860233 |
0.798 |
|
| 2012 |
Beaver JA, Park BH. The BOLERO-2 trial: The addition of everolimus to exemestane in the treatment of postmenopausal hormone receptor-positive advanced breast cancer Future Oncology. 8: 651-657. PMID 22764762 DOI: 10.2217/Fon.12.49 |
0.41 |
|
| 2012 |
Stopeck AT, Brown-Glaberman U, Wong HY, Park BH, Barnato SE, Gradishar WJ, Hudis CA, Rugo HS. The role of targeted therapy and biomarkers in breast cancer treatment. Clinical & Experimental Metastasis. 29: 807-19. PMID 22692561 DOI: 10.1007/S10585-012-9496-Y |
0.499 |
|
| 2012 |
Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Fetting J, Emens L, Riley C, Stearns V, Diehl F, Angenendt P, ... ... Park BH, et al. Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 3462-9. PMID 22421194 DOI: 10.1158/1078-0432.Ccr-11-2696 |
0.802 |
|
| 2012 |
Garay JP, Karakas B, Abukhdeir AM, Cosgrove DP, Gustin JP, Higgins MJ, Konishi H, Konishi Y, Lauring J, Mohseni M, Wang GM, Jelovac D, Weeraratna A, Sherman Baust CA, Morin PJ, ... ... Park BH, et al. The growth response to androgen receptor signaling in ERα-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Research : Bcr. 14: R27. PMID 22321971 DOI: 10.1186/Bcr3112 |
0.828 |
|
| 2012 |
Cimino-Mathews A, Hicks JL, Illei PB, Halushka MK, Fetting JH, De Marzo AM, Park BH, Argani P. Androgen receptor expression is usually maintained in initial surgically resected breast cancer metastases but is often lost in end-stage metastases found at autopsy Human Pathology. 43: 1003-1011. PMID 22154362 DOI: 10.1016/J.Humpath.2011.08.007 |
0.368 |
|
| 2012 |
Wu X, Sahasrabuddhe NA, Renuse S, Zahari S, Chaerkady R, Mohseni M, Yang J, Kim M, Zhong J, Qian J, Zhu H, Vogelstein B, Park BH, Pandey A. Abstract 985: Dissecting PI3K-AKT pathway by phosphoproteomic profiling of PIK3CA knock-in mutants Cancer Research. 72: 985-985. DOI: 10.1158/1538-7445.Am2012-985 |
0.845 |
|
| 2011 |
Higgins MJ, Jelovac D, Barnathan E, Blair B, Slater S, Powers P, Zorzi J, Jeter SC, Oliver GR, Diehl F, Angenendt P, Huang P, Argani P, Murphy K, Wolff AC, ... Park BH, et al. Improving detection methods for PIK3CA mutations in breast cancer using peripheral blood from patients with metastastic breast cancer (MBC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 10512. PMID 28021790 DOI: 10.1200/Jco.2011.29.15_Suppl.10512 |
0.817 |
|
| 2011 |
Kuo AJ, Cheung P, Chen K, Zee BM, Kioi M, Lauring J, Xi Y, Park BH, Shi X, Garcia BA, Li W, Gozani O. NSD2 links dimethylation of histone H3 at lysine 36 to oncogenic programming. Molecular Cell. 44: 609-20. PMID 22099308 DOI: 10.1016/J.Molcel.2011.08.042 |
0.304 |
|
| 2011 |
Lauring J, Park BH. BEAMing sheds light on drug resistance Clinical Cancer Research. 17: 7508-7510. PMID 22065078 DOI: 10.1158/1078-0432.Ccr-11-2556 |
0.459 |
|
| 2011 |
Konishi H, Mohseni M, Tamaki A, Garay JP, Croessmann S, Karnan S, Ota A, Wong HY, Konishi Y, Karakas B, Tahir K, Abukhdeir AM, Gustin JP, Cidado J, Wang GM, ... ... Park BH, et al. Mutation of a single allele of the cancer susceptibility gene BRCA1 leads to genomic instability in human breast epithelial cells. Proceedings of the National Academy of Sciences of the United States of America. 108: 17773-8. PMID 21987798 DOI: 10.1073/Pnas.1110969108 |
0.842 |
|
| 2011 |
Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, Hicks JL, Park BH, Humphreys E, Partin AW, Han M, Netto GJ, Isaacs WB, De Marzo AM. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6563-73. PMID 21878536 DOI: 10.1158/1078-0432.Ccr-11-1244 |
0.341 |
|
| 2011 |
Lewis GH, Subhawong AP, Nassar H, Vang R, Illei PB, Park BH, Argani P. Relationship between molecular subtype of invasive breast carcinoma and expression of gross cystic disease fluid protein 15 and mammaglobin. American Journal of Clinical Pathology. 135: 587-91. PMID 21411781 DOI: 10.1309/Ajcpmfr6Oa8Ichnh |
0.457 |
|
| 2011 |
Li HF, Keeton A, Vitolo M, Maddox C, Rasmussen L, Hobrath J, White EL, Park BH, Piazza GA, Kim JS, Waldman T. A high-throughput screen with isogenic PTEN+/+ and PTEN-/- cells identifies CID1340132 as a novel compound that induces apoptosis in PTEN and PIK3CA mutant human cancer cells. Journal of Biomolecular Screening. 16: 383-93. PMID 21335596 DOI: 10.1177/1087057110397357 |
0.521 |
|
| 2011 |
Higgins MJ, Beaver JA, Wong HY, Gustin JP, Lauring JD, Garay JP, Konishi H, Mohseni M, Wang GM, Cidado J, Jelovac D, Cosgrove DP, Tamaki A, Abukhdeir AM, Park BH. PIK3CA mutations and EGFR overexpression predict for lithium sensitivity in human breast epithelial cells. Cancer Biology & Therapy. 11: 358-67. PMID 21124076 DOI: 10.4161/Cbt.11.3.14227 |
0.842 |
|
| 2010 |
Jelovac D, Park BH. PTEN promoter silencing and Cowden syndrome: The role of epigenetic regulation of KILLIN Jama - Journal of the American Medical Association. 304: 2744-2745. PMID 21177512 DOI: 10.1001/Jama.2010.1863 |
0.514 |
|
| 2010 |
Mohseni M, Park BH. PIK3CA and KRAS mutations predict for response to everolimus therapy: Now that's RAD001 Journal of Clinical Investigation. 120: 2655-2658. PMID 20664174 DOI: 10.1172/Jci44026 |
0.821 |
|
| 2010 |
Weiss MB, Vitolo MI, Mohseni M, Rosen DM, Denmeade SR, Park BH, Weber DJ, Bachman KE. Deletion of p53 in human mammary epithelial cells causes chromosomal instability and altered therapeutic response. Oncogene. 29: 4715-24. PMID 20562907 DOI: 10.1038/Onc.2010.220 |
0.813 |
|
| 2010 |
Lauring J, Cosgrove DP, Fontana S, Gustin JP, Konishi H, Abukhdeir AM, Garay JP, Mohseni M, Wang GM, Higgins MJ, Gorkin D, Reis M, Vogelstein B, Polyak K, Cowherd M, ... ... Park BH, et al. Knock in of the AKT1 E17K mutation in human breast epithelial cells does not recapitulate oncogenic PIK3CA mutations Oncogene. 29: 2337-2345. PMID 20101210 DOI: 10.1038/Onc.2009.516 |
0.845 |
|
| 2010 |
Karnan S, Mohseni M, Konishi Y, Tamaki A, Hosokawa Y, Park BH, Konishi H. Controversial BRCA1 allelotypes in commonly used breast cancer cell lines. Breast Cancer Research and Treatment. 119: 249-51. PMID 19585236 DOI: 10.1007/S10549-009-0465-3 |
0.824 |
|
| 2010 |
Krop I, Wolff A, Winer E, Miller K, Park B, Ware J, Holden S, Levy G, Derynck M, Storniolo A. Abstract P6-15-02: A Phase Ib Study Evaluating Safety, Tolerability, Pharmacokinetics (PK), and Activity of the Phosphoinositide-3 Kinase (PI3K) Inhibitor GDC-0941 in Combination with Trastuzumab-MCC-DM1 (T-DM1) in Patients with Advanced HER2-Positive Breast Cancer Cancer Research. 70. DOI: 10.1158/0008-5472.Sabcs10-P6-15-02 |
0.413 |
|
| 2010 |
Wang GM, Park BH. The role of PIK3CA mutations as a predictor of outcomes and a therapeutic target Current Breast Cancer Reports. 2: 167-173. DOI: 10.1007/S12609-010-0022-4 |
0.569 |
|
| 2009 |
Higgins MJ, Abukhdeir AM, Gustin J, Vitolo MI, Bachman KE, Park BH. Preclinical study of lithium sensitivity in human breast PTEN knock out cell lines. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e14641. PMID 27964232 DOI: 10.1200/Jco.2009.27.15_Suppl.E14641 |
0.854 |
|
| 2009 |
Vitolo MI, Weiss MB, Szmacinski M, Tahir K, Waldman T, Park BH, Martin SS, Weber DJ, Bachman KE. Deletion of PTEN promotes tumorigenic signaling, resistance to anoikis, and altered response to chemotherapeutic agents in human mammary epithelial cells. Cancer Research. 69: 8275-83. PMID 19843859 DOI: 10.1158/0008-5472.Can-09-1067 |
0.54 |
|
| 2009 |
Higgins MJ, Park BH. Expanding role of bisphosphonates in the management of early breast cancer. Expert Review of Anticancer Therapy. 9: 1051-4. PMID 19671024 DOI: 10.1586/Era.09.70 |
0.471 |
|
| 2009 |
Gustin JP, Karakas B, Weiss MB, Abukhdeir AM, Lauring J, Garay JP, Cosgrove D, Tamaki A, Konishi H, Konishi Y, Mohseni M, Wang G, Rosen DM, Denmeade SR, Higgins MJ, ... ... Park BH, et al. Knockin of mutant PIK3CA activates multiple oncogenic pathways. Proceedings of the National Academy of Sciences of the United States of America. 106: 2835-40. PMID 19196980 DOI: 10.1073/Pnas.0813351106 |
0.852 |
|
| 2009 |
Hansel DE, Nakayama M, Luo J, Abukhdeir AM, Park BH, Bieberich CJ, Hicks JL, Eisenberger M, Nelson WG, Mostwin JL, De Marzo AM. Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate. The Prostate. 69: 603-9. PMID 19125417 DOI: 10.1002/Pros.20910 |
0.315 |
|
| 2009 |
Higgins MJ, Park BH. Expanding role of bisphosphonates in the management of early breast cancer Expert Review of Anticancer Therapy. 9: 1051-1054. DOI: 10.1586/ERA.09.70 |
0.354 |
|
| 2008 |
Gustin JP, Cosgrove DP, Park BH. The PIK3CA gene as a mutated target for cancer therapy. Current Cancer Drug Targets. 8: 733-40. PMID 19075596 DOI: 10.2174/156800908786733504 |
0.827 |
|
| 2008 |
Leary RJ, Lin JC, Cummins J, Boca S, Wood LD, Parsons DW, Jones S, Sjöblom T, Park BH, Parsons R, Willis J, Dawson D, Willson JK, Nikolskaya T, Nikolsky Y, et al. Integrated analysis of homozygous deletions, focal amplifications, and sequence alterations in breast and colorectal cancers. Proceedings of the National Academy of Sciences of the United States of America. 105: 16224-9. PMID 18852474 DOI: 10.1073/Pnas.0808041105 |
0.832 |
|
| 2008 |
Abukhdeir AM, Park BH. p21 and p27: Roles in carcinogenesis and drug resistance Expert Reviews in Molecular Medicine. 10. PMID 18590585 DOI: 10.1017/S1462399408000744 |
0.364 |
|
| 2008 |
Abukhdeir AM, Vitolo MI, Argani P, De Marzo AM, Karakas B, Konishi H, Gustin JP, Lauring J, Garay JP, Pendleton C, Konishi Y, Blair BG, Brenner K, Garrett-Mayer E, Carraway H, ... ... Park BH, et al. Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proceedings of the National Academy of Sciences of the United States of America. 105: 288-93. PMID 18162533 DOI: 10.1073/Pnas.0710887105 |
0.842 |
|
| 2008 |
Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH. The multiple myeloma associated MMSET gene contributes to cellular adhesion, clonogenic growth, and tumorigenicity. Blood. 111: 856-64. PMID 17942756 DOI: 10.1182/Blood-2007-05-088674 |
0.792 |
|
| 2007 |
Konishi H, Lauring J, Garay JP, Karakas B, Abukhdeir AM, Gustin JP, Konishi Y, Park BH. A PCR-based high-throughput screen with multiround sample pooling: application to somatic cell gene targeting. Nature Protocols. 2: 2865-74. PMID 18007621 DOI: 10.1038/Nprot.2007.409 |
0.779 |
|
| 2007 |
Park BH, Davidson NE. PI3 Kinase Activation and Response to Trastuzumab Therapy: What's neu with Herceptin Resistance? Cancer Cell. 12: 297-299. PMID 17936554 DOI: 10.1016/J.Ccr.2007.10.004 |
0.471 |
|
| 2007 |
Wood LD, Parsons DW, Jones S, Lin J, Sjöblom T, Leary RJ, Shen D, Boca SM, Barber T, Ptak J, Silliman N, Szabo S, Dezso Z, Ustyanksky V, Nikolskaya T, ... ... Park BH, et al. The genomic landscapes of human breast and colorectal cancers. Science (New York, N.Y.). 318: 1108-13. PMID 17932254 DOI: 10.1126/science.1145720 |
0.826 |
|
| 2007 |
Konishi H, Karakas B, Abukhdeir AM, Lauring J, Gustin JP, Garay JP, Konishi Y, Gallmeier E, Bachman KE, Park BH. Knock-in of mutant K-ras in nontumorigenic human epithelial cells as a new model for studying K-ras mediated transformation. Cancer Research. 67: 8460-7. PMID 17875684 DOI: 10.1158/0008-5472.Can-07-0108 |
0.812 |
|
| 2007 |
Karakas B, Weeraratna AT, Abukhdeir AM, Konishi H, Gustin JP, Vitolo MI, Bachman KE, Park BH. P21 gene knock down does not identify genetic effectors seen with gene knock out. Cancer Biology & Therapy. 6: 1025-30. PMID 17611398 DOI: 10.4161/Cbt.6.7.4202 |
0.779 |
|
| 2007 |
Sui M, Huang Y, Park BH, Davidson NE, Fan W. Estrogen receptor alpha mediates breast cancer cell resistance to paclitaxel through inhibition of apoptotic cell death. Cancer Research. 67: 5337-44. PMID 17545614 DOI: 10.1158/0008-5472.Can-06-4582 |
0.503 |
|
| 2007 |
Weiss MB, Vitolo MI, Baerenfaller K, Marra G, Park BH, Bachman KE. Persistent mismatch repair deficiency following targeted correction of hMLH1. Cancer Gene Therapy. 14: 98-104. PMID 17082796 DOI: 10.1038/Sj.Cgt.7700997 |
0.508 |
|
| 2007 |
Lauring J, Abukhdeir AM, Konishi H, Garay JP, Gustin JP, Wang Q, Arceci RJ, Matsui W, Park BH. The MMSET Gene Contributes to the Growth, Adhesion, and Tumorigencitiy of t(4;14) Multiple Myeloma Cells. Blood. 110: 2636-2636. DOI: 10.1182/Blood.V110.11.2636.2636 |
0.793 |
|
| 2007 |
Parmigiani G, Lin J, Boca SM, Sjöblom T, Jones S, Wood LD, Parsons DW, Barber T, Buckhaults P, Markowitz SD, Park BH, Bachman KE, Papadopoulos N, Vogelstein B, Kinzler KW, et al. Response to comments on "The consensus coding sequences of human breast and colorectal cancers" Science. 317: 1500d. DOI: 10.1126/Science.1138773 |
0.739 |
|
| 2006 |
Sjöblom T, Jones S, Wood LD, Parsons DW, Lin J, Barber TD, Mandelker D, Leary RJ, Ptak J, Silliman N, Szabo S, Buckhaults P, Farrell C, Meeh P, Markowitz SD, ... ... Park BH, et al. The consensus coding sequences of human breast and colorectal cancers Science. 314: 268-274. PMID 16959974 DOI: 10.1126/science.1133427 |
0.763 |
|
| 2006 |
Huang Y, Keen JC, Pledgie A, Marton LJ, Zhu T, Sukumar S, Park BH, Blair B, Brenner K, Casero RA, Davidson NE. Polyamine analogues down-regulate estrogen receptor alpha expression in human breast cancer cells. The Journal of Biological Chemistry. 281: 19055-63. PMID 16679312 DOI: 10.1074/Jbc.M600910200 |
0.799 |
|
| 2006 |
Karakas B, Weeraratna A, Abukhdeir A, Blair BG, Konishi H, Arena S, Becker K, Wood W, Argani P, De Marzo AM, Bachman KE, Park BH. Interleukin-1 alpha mediates the growth proliferative effects of transforming growth factor-beta in p21 null MCF-10A human mammary epithelial cells. Oncogene. 25: 5561-9. PMID 16619041 DOI: 10.1038/Sj.Onc.1209540 |
0.312 |
|
| 2006 |
Abukhdeir AM, Blair BG, Brenner K, Karakas B, Konishi H, Lim J, Sahasranaman V, Huang Y, Keen J, Davidson N, Vitolo MI, Bachman KE, Park BH. Physiologic estrogen receptor alpha signaling in non-tumorigenic human mammary epithelial cells. Breast Cancer Research and Treatment. 99: 23-33. PMID 16541319 DOI: 10.1007/S10549-006-9177-0 |
0.799 |
|
| 2006 |
Karakas B, Bachman KE, Park BH. Mutation of the PIK3CA oncogene in human cancers British Journal of Cancer. 94: 455-459. PMID 16449998 DOI: 10.1038/Sj.Bjc.6602970 |
0.53 |
|
| 2005 |
Keen JC, Zhou Q, Park BH, Pettit C, Mack KM, Blair B, Brenner K, Davidson NE. Protein phosphatase 2A regulates estrogen receptor alpha (ER) expression through modulation of ER mRNA stability. The Journal of Biological Chemistry. 280: 29519-24. PMID 15965230 DOI: 10.1074/jbc.M505317200 |
0.743 |
|
| 2005 |
Bachman KE, Sager J, Cheong I, Catto M, Bardelli A, Park BH, Vogelstein B, Carotti A, Kinzler KW, Lengauer C. Identification of compounds that inhibit growth of 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine-resistant cancer cells Molecular Cancer Therapeutics. 4: 1026-1030. PMID 15956261 DOI: 10.1158/1535-7163.Mct-05-0038 |
0.757 |
|
| 2005 |
Bachman KE, Park BH. Duel nature of TGF-beta signaling: tumor suppressor vs. tumor promoter. Current Opinion in Oncology. 17: 49-54. PMID 15608513 DOI: 10.1097/01.Cco.0000143682.45316.Ae |
0.326 |
|
| 2004 |
Bachman KE, Argani P, Samuels Y, Silliman N, Ptak J, Szabo S, Konishi H, Karakas B, Blair BG, Lin C, Peters BA, Velculescu VE, Park BH. The PIK3CA gene is mutated with high frequency in human breast cancers. Cancer Biology & Therapy. 3: 772-5. PMID 15254419 DOI: 10.4161/Cbt.3.8.994 |
0.833 |
|
| 2004 |
Park BH, Davidson NE. Estrogen receptor status, cell cycling and paclitaxel: looking for a "hormone"-ious explanation. Cancer Biology & Therapy. 3: 468-9. PMID 15153814 DOI: 10.4161/Cbt.3.5.832 |
0.344 |
|
| 2004 |
Bachman KE, Blair BG, Brenner K, Bardelli A, Arena S, Zhou S, Hicks J, De Marzo AM, Argani P, Park BH. p21(WAF1/CIP1) mediates the growth response to TGF-beta in human epithelial cells. Cancer Biology & Therapy. 3: 221-5. PMID 14726675 |
0.746 |
|
| 2003 |
Bachman KE, Park BH, Rhee I, Rajagopalan H, Herman JG, Baylin SB, Kinzler KW, Vogelstein B. Histone modifications and silencing prior to DNA methylation of a tumor suppressor gene Cancer Cell. 3: 89-95. PMID 12559178 DOI: 10.1016/S1535-6108(02)00234-9 |
0.453 |
|
| 2002 |
Rhee I, Bachman KE, Park BH, Jair KW, Yen RW, Schuebel KE, Cui H, Feinberg AP, Lengauer C, Kinzler KW, Baylin SB, Vogelstein B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature. 416: 552-6. PMID 11932749 DOI: 10.1038/416552A |
0.697 |
|
| 2001 |
Park BH, Vogelstein B, Kinzler KW. Genetic disruption of PPARδ decreases the tumorigenicity of human colon cancer cells Proceedings of the National Academy of Sciences of the United States of America. 98: 2598-2603. PMID 11226285 DOI: 10.1073/Pnas.051630998 |
0.586 |
|
| 2001 |
Park BH, Breyer B, He TC. Peroxisome proliferator-activated receptors: Roles in tumorigenesis and chemoprevention in human cancer Current Opinion in Oncology. 13: 78-83. PMID 11148691 DOI: 10.1097/00001622-200101000-00015 |
0.319 |
|
| 2000 |
Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B. Role of BAX in the apoptotic response to anticancer agents. Science (New York, N.Y.). 290: 989-92. PMID 11062132 DOI: 10.1126/Science.290.5493.989 |
0.602 |
|
| 1991 |
Teng MN, Park BH, Koeppen HK, Tracey KJ, Fendly BM, Schreiber H. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proceedings of the National Academy of Sciences of the United States of America. 88: 3535-9. PMID 2023898 DOI: 10.1073/Pnas.88.9.3535 |
0.336 |
|
| Show low-probability matches. |